Kornimate/medical-research-clean huggingface dataset:
mangement of pulmonary emboli

Conditions: Pulmonary Embolism (Diagnosis)

Summary: to assess to which extent we are adherent to esc guidelines 2019 in management of patients presented with acute pulmonary embolism

pulmonary embolism (pe) is the third most frequent cardiovascular disease and is associated with a high mortality burden pe is defined as the obstruction of a pulmonary artery, mostly resulting from the dislodgement of thrombotic material from the lower limbs. it has a wide variety of presentations, ranging from an asymptomatic incidental finding to circulatory collapse and sudden death pulmonary embolism response teams (perts) have emerged as a multidisciplinary team for managing acute pulmonary embolism, with a rapid activation process for multimodality assessment, risk stratification and best management especially for complex challenge cases. perts help in improving time to pe diagnosis; shorter time to initiation of anticoagulation reducing hospital length of stay, increasing use of advanced therapies as catheter directed therapies without an increase in bleeding complications with decreasing mortality

Eligibility criteria:
inclusion criteria: * no includion criteria exclusion criteria: * no exclusion criteria

Keywords: simplified pulmonary embolism l index pope
a brief mindfulness-based intervention for suicidal ideation

Conditions: Suicidal Ideation; Psychiatric Disorder; Addiction

Summary: the primary aim of this study is to determine whether a brief mindfulness-based intervention for suicidal ideation (mb-si) is feasible and safe to implement. the secondary aims are short and longer-term reduction in suicidal ideation (si) and/or suicide-related behaviors (srbs) as well as improvements in mindfulness and emotional regulation measures compared to treatment as usual (tau).

the study feasibility will be assessed through participant enrollment and retention numbers. the safety be monitored by the study personnel and include reporting any adverse effects. the intervention fidelity will be aided by standardizing the intervention and ensuring study personnel has the appropriate trainings. participants will completed questionnaires assessing their si and srb as well as mindfulness and emotional regulation measures at three time points (preintervention, immediately postintervention, and 1-month postintervention) and their results will be compared between mb-si and tau groups. additionally, the comparisons will also be conducted for the emergency department (ed) admissions, inpatient psychiatric unit (ipu) admissions, and psychiatric ed admissions.

Eligibility criteria:
inclusion criteria: * admitted with suicidal ideation and any active psychiatric or addictive disorder diagnosis. exclusion criteria: * diagnosis of psychotic spectrum illness and current psychotic symptoms or significant cognitive impairment.

Keywords: mindfulness suicide related behavior veterans veterans' affairs suicidal ideation
safety, tolerability, and pharmacokinetics of single and multiple doses of ht-100 in duchenne muscular dystrophy

Conditions: Duchenne Muscular Dystrophy

Summary: the main purpose of this study is to test the safety and tolerability of different, increasing doses of an experimental medication called ht-100 in boys and young men with duchenne muscular dystrophy (dmd). the study medication, ht-100, is a medicine that may help promote healthy muscle regeneration, diminish inflammation and the resulting damage to muscle, and decrease the scar tissue that forms in the muscles of children with dmd. in this study, pharmacokinetic sampling, or measurements of the amount of ht-100 in the bloodstream will also be taken.


Eligibility criteria:
main inclusion criteria: * ambulatory or non-ambulatory * diagnosis of dmd with confirmation of minimal to no dystrophin * corticosteroid naive or on therapy for at least 12 months (stable dose and regimen) main exclusion criteria: * recent, substantial change in use of cardiac medications or medications affecting muscle function * inability to undergo magnetic resonance imaging (mri) * significantly compromised cardio-respiratory function * prior treatment with another investigational product in past 6 months

Keywords: halofuginone hydrobromide anti-fibrotic anti-inflammatory muscle regeneration protein synthesis inhibitor
bumblebee breath effect on tinnitus in older patients

Conditions: Tinnitus, Subjective

Summary: tinnitus is a condition in which the person hears sound, which isn't coming from the external environment, often, described as ringing in the ears. patients describe the condition as an annoyance and disturbance and in turn this correlates with increased levels of anxiety and depression. currently, there is no single effective treatment for tinnitus so research continues to look for new ways to treat and manage the condition. bumblebee breath starts by finding a relaxed, supported posture, either laying supine or in seated and then bringing the minds attention to the space between the eyebrows (or third eye in yoga terms). with the eyes close the thumbs are placed over the tragus of the ears, the first finger gently rests on eye lids, middle finger touches the sides of the nose and then the index and pinkie rest just above and below the closed lips. next, a sound is created by inhaling deeply through the nose and exhaling with a low-pitched humming sound. the result sounds very much like a bee buzzing to the person performing the breath and a sensation of vibration is experienced inside the head and over the face. this study is designed to assess bumblebee breath on tinnitus.

two groups (28 for each) will included. one tinnitus group will receive half an hour of bumblebee breath training (daily) for one month. the second one will receive nothing

Eligibility criteria:
inclusion criteria: * elderly males and females * tinnitus complaints exclusion criteria: * cardio(respiratory) symptoms, any local (within ear) problem(s).
dose-finding study using pentostatin for injection in the treatment of steroid-refractory agvhd

Conditions: Acute Graft Versus Host Disease

Summary: to determine a safe and effective dose of pentostatin in steroid-refractory agvhd and to identify the minimal effective dose of pentostatin defined as the lowest dose that produces a response in 20% or more of patients while producing treatment failure (defines as death, grade 3/4 toxicity, or progressive disease) in 40% or less of patients.


Eligibility criteria:
inclusion: * patients 6 months of age with grade 2 gvhd that is steroid-refractory * must be engrafted with anc 1000/ml, may still be transfusion dependent for platelets and prbc * time post stem cell infusion \< 100 days * written informed consent * must have adequate renal function (creatinine clearance 40 ml/min/1.73 m2) exclusion: * post-transplant lymphoproliferative disease * uncontrolled infection * mental illness or other condition preventing full cooperation with the treatment and monitoring requirements of the study * atg within the previous 14 days * other immunosuppressive agents (including monoclonal antibodies) when initiated within the previous 7 days

Keywords: acute graft versus host disease agvhd allogeneic hematopoietic stem cell transplantation peripheral blood stem cell transplantation cord blood transplant pentostatin nipent deoxycoformycin
efficacy of cpr teaching in mass training

Conditions: Teaching CPR

Summary: this prospective study evaluate teaching efficacy of cpr training using different methods in general population, medical students and non medical students with the 12 months evaluation of its recall

in a prospective and observational study of 2000 individuals in three different groups including medical students, non-medical students and general populations four different protocols of cpr training were applied and their efficacy were compared between the groups. meanwhile, 12 months after the study course, 460 participants from three groups were asked to take part in a theoretical and practical exam to evaluate the long term efficacy of the four protocols.

Eligibility criteria:
inclusion criteria: * all participant take part in workshop exclusion criteria: * refuse to take part in exams

Keywords: cardiac arrest cardiopulmonary resuscitation training
applicability of cellular application in diabetes type 2 patients.

Conditions: Diabetes Mellitus, Type 2

Summary: it was found that an important part of the factors impeding adherence to medication and a healthy lifestyle among the chronically ill diabetic patients lies in proper management of the disease. since it is a chronic progressive disease the caregiver is the patient himself.studies have shown that software system, sending text messages / messages / reminders daily and answering questionnaires can improve adherence to a change in lifestyle. this study is an initial pilot study , which examines feasibility ( applicability ) of using a smart application that promotes a healthy lifestyle perseverance parallel use relaxation techniques .


Eligibility criteria:
inclusion criteria: * hba1c above 7.5. * smartphone users. * english and hebrew literate. exclusion criteria: \*pregnancy
study to evaluate efficacy and safety in chinese patients with late onset pompe disease with alglucosidase alfa treatmen

Conditions: Pompe's Disease

Summary: primary objective: to evaluate the effect of one-year alglucosidase alfa treatment on motor function \[six-minute walk test (6mwt) and lung function predicted forced vital capacity (fvc)\] among chinese late onset pompe disease patients above 5 years old. to evaluate the safety of myozyme 20mg/kg, iv biweekly in chinese lopd patients above 3 years old. secondary objective: to evaluate the effect of one-year treatment with alglucosidase alfa on improvement of manual muscle test (mmt), maximal inspiratory and expiratory pressure (mip and mep)\], quick motor function test scores, and health-related quality of life (sf-12) among lopd patients over 5 years old.

study duration per participants is approximatively 56 weeks including a 52-week treatment period.

Eligibility criteria:
inclusion criteria : * patients (or and patient's legal guardian) must provide written informed consent prior to any study-related procedures * the patient must be ≥ 3 years of age at the time of enrollment. 1. for patient ≥ 3-year and \< 5-year old: must be able to walk 10 meters or climb 4-step stairs independently. 2. for patients ≥5-year old i. must be able to ambulate 40 meters in 6 minutes without assistance ii. must be able to successfully perform repeated forced vital capacity (vc) measurements in upright position of ≥ 30% predicted and ≤85% predicted. * the patient has confirmed pompe's disease with at least 2 of the following condition, 1. gaa enzyme deficiency from any tissue source. 2. 2 confirmed gaa gene mutations. 3. muscle pathology meet the diagnosis of pompe disease. * the patient (and patient's legal guardian if patient is legally minor as defined by local regulation) must have the ability to comply with the clinical protocol. * the patient, if female and of childbearing potential, must have a negative pregnancy test (beta-human chorionic gonadotropin) at baseline. exclusion criteria: * use of invasive ventilatory support (invasive ventilation is defined as any form of ventilatory support applied with the use of an endotracheal tube.) * use of non-invasive ventilatory support while awake and in an upright position. (non-invasive ventilation is defined as any form of ventilatory support applied without the use of an endotracheal tube.) * previously treated with enzyme replacement treatment. * a female patient of childbearing potential with a positive pregnancy test. * wheelchair dependent. * the patient has a major congenital anomaly. * the patient has a medical condition, serious intercurrent illness, or other extenuating circumstance, in the opinion of the investigator, may significantly interfere with study compliance, including all prescribed evaluations and follow-up activities. * the patients with ≥5-year old are unable to ambulate 40 meters without assistance or unable to successfully perform repeated fvc of \>30% and \<85% predicted (upright). the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
urdu version of the bournemouth questionnaire for neck pain: a reliability and validity study

Conditions: Neck Pain

Summary: the aim of study is to translate \& culturally adapt neck bournemouth questionnaire into urdu language along with investigation of the reliability \& validity of neck bournemouth questionnaire in general population of pakistan and to correlate with neck disability index, visual analogue scale, neck pain and disability scale and rand 36-item health survey

the english version of the bournemouth questionnaire for neck pain will be translated and culturally adapted as per as previous recommendations. in the general population with neck pain, urdu version of the bournemouth questionnaire for neck pain will be distributed among participants by choosing convenience sampling technique based on predefined inclusion and exclusion criteria. test inter and intra- observer reliability of the final urdu version of the bournemouth questionnaire for neck pain with neck disability index, neck pain and disability scale, visual analogue scale, and rand will be filled with same day, by two observers and for the inter-observers assessment, with an interval of 45 minutes between the first and second application. third assessment will be carried out after 7 days by observer-1(re-intra-observers assessment. data will be entered and analyzed by cronbach alpha value. test -retest reliability will be assessed using interclass correlation coefficient. the urdu version of the bournemouth questionnaire for neck pain will be evaluated for content validity, construct validity, criterion validity and responsiveness.

Eligibility criteria:
inclusion criteria: * 18 to 65 years of age * 3 months of neck pain * neck pain more than six moth * male female both genders * physician referral * not prescribed medicine * without deformity in neck * ability of reading and writing exclusion criteria: * joint inflammation or infection * pathology of shoulder * fibromylgia * psychologically unstable or having neurological disorder * cancer history * cervical injury * took treatment of physical therapy in last 6 month * any disability * loss of memory * disease or any red flag * using neck immobilization device

Keywords: bournemouth questionnaire for neck pain neck pain cultural adaptation validity urdu version reliability
change in ocular perfusion after intravitreal anti-vegf in patients with age-related maculopathy or diabetic macula edema

Conditions: Age Related Macular Degeneration; Diabetic Macular Edema

Summary: this prospective study will include patients with neovascular age-related macular degeneration or diabetic macular edema, scheduled for intravitreal aflibercept. ocular perfusion will be measured by laser speckle flowgraphy (lsfg). the parameter mean blur rate (mbr) reflects erythrocyte flow velocity and serves as an indirect marker of perfusion. mbr will be measured at the optic nerve head (onh). the devices software can analyze mbr in areas of major retinal vessels (mv) and in microperfusion areas (mt) separately. measurements will be conducted on the day of the planned intravitreal injection and one and four weeks post-injection.


Eligibility criteria:
inclusion criteria: * age \> 50 years, * patients scheduled for an intravitreal injections with aflibercept for treatment of dme or amd. exclusion criteria: * ocular surgery (including intravitreal injection) during the 3 months preceding the study * ametropia \> 6 dpt * any relevant ophthalmic diseases/conditions that could interfere with lsfg measurements (e.g. glaucoma, optic nerve head drusen, tilted disc, etc.).

Keywords: ocular perfusion laser speckle flowgraphy anti-vegf
surgical treatment of type 2 diabetes in non-morbidly obese patients

Conditions: Diabetes

Summary: the aim of this study is to assess the short term success and feasibility of ileal transposition with sleeve gastrectomy in non-morbidly obese patients with poorly controlled type 2 diabetes mellitus


Eligibility criteria:
inclusion criteria: 1. diagnosed type 2 diabetes for 3 to 5 years. 2. poorly controlled blood sugar despite standard of care\* as demonstrated by hba1c 8-11 for at least 6 months and 3 office visits. standard of care is based on the ada (american diabetes association) guidelines which include nutrition, exercise, education, behavior modification and pharmacological treatment. a co-investigator endocrinologist will ensure that the above standard of care has been met. 3. bmi between 25.0 and 34.4. 4. stable weight as determined by no more than a 3% change in body weight in the last 3 months. 5. age between 35 and 65 (both men and women will be included). 6. able to provide informed consent. 7. able to comply with follow-up procedures. exclusion criteria: 1. previous history of major abdominal surgery which may lead to a hostile abdomen. 2. pregnancy 3. patients who have an incurable malignant or debilitating disease 4. serious uncorrectable impairment of coagulation (inr\>1.4, ptt \> + 3 secs), lungs, kidney or heart 5. diagnosed severe eating disorder 6. use of medication for weight loss in the last 6 months 7. untreated endocrine disorder 8. active peptic ulcer 9. untreated h. pylori 10. cognitive impairment 11. diabetic autonomic neuropathy 12. symptomatic gastroparesis
phase 3 study of futuximab/modotuximab in combination with trifluridine/tipiracil versus trifluridine/tipiracil single agent in participants with previously treated metastatic colorectal cancer

Conditions: Metastatic Colorectal Cancer

Summary: this is a randomized phase iii study with a safety lead-in part in patients with kras/ nras and braf wild type metastatic colorectal cancer who have previously received treatment with oxaliplatin, irinotecan, fluoropyrimidines, anti-vegf agents and anti-egfr antibodies. the main objective of the safety lead-in part is to assess safety and tolerability of futuximab/modotuximab in combination with trifluridine/tipiracil. the primary objective of the phase iii part is to compare overall survival of futuximab/modotuximab in combination with trifluridine/tipiracil vs trifluridine/tipiracil monotherapy in patients with tumours that are kras/nras and braf wild-type (wt).


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed adenocarcinoma of metastatic colorectal cancer (mcrc), not amenable to surgical intervention due to either medical contraindications or non-resectability of the tumour without ras (kras and nras) and braf v600e mutations based on circulating tumour dna (ctdna) screening blood test analysis * participants with measurable or non-measurable lesion * participants must have received at least 2 prior regimens of standard chemotherapy for mcrc and had demonstrated progressive disease or intolerance to their last regimen * participants should have received previous treatment with commercially available anti-egfr mabs for ≥ 4 months * estimated life expectancy ≥ 12 weeks * eastern cooperative oncology group (ecog) performance status 0 or 1 * adequate haematological, renal and hepatic function exclusion criteria: * pregnancy, possibility of becoming pregnant during the study, breastfeeding woman * patients currently receiving or having received anticancer therapies within 4 weeks prior to the inclusion visit (safety lead-in part) or randomization visit (phase 3 part). * major surgery within 4 weeks prior to the inclusion visit (safety lead-in part) or randomization visit (phase 3 part) or participants who have not recovered from side effects of the surgery * participants with serious/active/uncontrolled infection * known clinically significant cardiovascular disease or condition * significant gastrointestinal abnormality * skin rash of grade \> 1 from prior anti-egfr at the time of inclusion (safety lead-in part) or randomization (phase 3 part), or any other skin toxicity precluding participation in the study according to investigator's discretion. * treatment with systemic immunosuppressive therapy within 4 weeks prior to inclusion (safety lead-in part) or randomization (phase 3 part) * prior radiotherapy if completed less than 4 weeks before the inclusion visit (safety lead-in part) or randomization visit (phase 3 part) * patients with other malignancies

Keywords: futuximab/modotuximab trifluridine/tipiracil phase iii safety lead-in part s95026 sym004 adult metastatic colorectal colorectal cancer egfr
effects of dry needling on spasticity and functional ability

Conditions: Cerebral Palsy (CP)

Summary: this study investigates the effects of dry needling on spasticity and its impact on functional ability in individuals with neuromuscular disorders. using the modified ashworth scale (mas), timed up and go (tug) test, and gross motor function measure (gmfm), the research evaluates changes in muscle tone, mobility, and overall motor performance following dry needling intervention. the findings aim to provide evidence on the clinical benefits of dry needling as a therapeutic approach for improving movement efficiency and functional outcomes in patients with spasticity.

spasticity is a common impairment in individuals with neuromuscular disorders, often leading to limitations in movement, balance, and overall functional performance. dry needling has emerged as a promising intervention for managing spasticity by targeting hyperactive muscle fibers and reducing abnormal muscle tone. this study aims to explore the therapeutic effects of dry needling on muscle spasticity and functional ability using standardized clinical measures. participants will undergo pre- and post-intervention assessments using the modified ashworth scale (mas) to quantify changes in muscle tone, the timed up and go (tug) test to evaluate mobility and balance, and the gross motor function measure (gmfm) to assess functional motor skills. the intervention will focus on specific muscle groups affected by spasticity. by analyzing the relationship between changes in spasticity and functional mobility, this study seeks to determine whether dry needling contributes to measurable improvements in movement efficiency, postural control, and daily functional activities. the findings will provide valuable insights into the role of dry needling as an adjunct therapy in rehabilitation programs, supporting its integration into clinical practice for individuals with neuromuscular disorders.

Eligibility criteria:
inclusion criteria: * hypertonia score 2 according to mas * able to understand and follow instructions * able to stand and walk independantly exclusion criteria: * participants with neurological conditions that involve significant cognitive deficits or severe uncontrolled epilepsy * participants who have undergone surgical procedures within the last 3 months

Keywords: dry needle spasticity functional abilities